Itruvone is under clinical development by VistaGen Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Itruvone’s likelihood of approval (LoA) and phase transition for Major Depressive Disorder took place on 12 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Itruvone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PH-10 is under development for the treatment of major depressive disorder. It belongs to a family of pharmaceutical compounds called pherines. It is administered intranasally as a spray. It is a psychoactive therapeutic agent.
VistaGen Therapeutics overview
VistaGen Therapeutics (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate receptor glycine B intended to treat the major depressive disorder. Its other pipeline products comprise of PH94B treats social anxiety disorder and PH10 nasal spray treats for major depressive disorder. The company offers its products in the form of sprays and oral. It partners with other healthcare industries for researching and assessing drug effects on cardiac risk. VistaGen is headquartered in South San Francisco, California, the US.
Quick View Itruvone LOA Data
|Highest Development Stage|